

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

REMARKS/ARGUMENTS

Claims 20-29 are pending in the present application. Claims 1-19 are canceled without prejudice. Applicants reserve the right to file a divisional application to prosecute claims 1-19. Claim 29 is newly added, which further makes clear that the dye in the originally recited "staining solution" of "a reagent for staining bacteria" is "capable of staining bacteria". Support for the amendment can be found, at, for example, page 10, line 13-page 14, line 16. No new matter is entered in the present amendment. In fact, it is Applicants' opinion that a person of ordinary skill in the art would understand that the dye in the previously presented claim 20 is capable of staining bacteria, given the context of claim 20, although claim 20 does not explicitly recite so. Hence, the addition of claim 29 would not incur any consideration more than cursory review from the Examiner. Entry of claim 29 is respectfully requested. It is respectfully requested that the Examiner reconsider the rejections based on the following remarks.

Claim Listing

The Examiner pointed out that Applicants' previous amendment did not comply with the new Claim Listing rule under 37 C.F.R. 1.121 (c). In response, this defect has been obviated in the present amendment.

Election/Restriction

As the result of an earlier restriction requirement, non-elected claims 1-19 has been canceled. Applicants retain the right to present claims 1-19 in a divisional application. Claims 20-29 are pending in the present application for the Examiner's consideration.

Anticipation Rejections Under 35 U.S.C. 102

Claims 20, 21, and 25 were rejected as being anticipated by Jackson (U.S. Patent 5,688,011) under 35 U.S.C. 102. Jackson '011 describes a test kit for determining the presence of *helicobacter pylori* using

urease as a marker enzyme. The described kit contains bromophenol blue dye, Tris buffer, and sulfamic acid (col. 2, lines 18-32). The presently pending claim 20 recites a reagent for staining bacteria comprising a staining solution containing a dye; and a diluent containing a buffer for maintaining acidity and an effective amount of a substance capable of reducing nitrite ions. Hence, the Examiner stated that each limitation of claim 20 and 21 of the present invention has been taught by Jackson '011, and therefore rejected claim 20 and 21 as being anticipated by Jackson '011. The Examiner further inferred that since the prior art reagent contains all of the claimed ingredients and can be maintained at the recited pH of claim 25, it is thereby deemed that claim 25 was also anticipated by Jackson '011.

Applicants respectfully traverse. Firstly, Tris buffer of Jackson '011 has a buffering effect between neutral to weakly alkaline, which is evidenced by, e.g. Exhibit 1 as herein enclosed with the present amendment. Hence, Tris buffer is not a buffer for maintaining acidity as recited in claim 20. Under the U.S. patent law, to anticipate a claim, each and every limitation of the claims must be disclosed inherently or expressly by a single prior art reference. Accordingly, none of claims 20, 21 and 25 is anticipated for at least the reason that the limitation of "a buffer for maintaining acidity" is not disclosed by the cited prior art, Jackson '011.

Secondly, the reagent for staining bacteria of claim 20 comprises a staining solution containing a dye. As noted above, Jackson '011 determines the presence of *H. Pylori* by detecting the presence of urease because it is well known that the enzyme urease is always associated with *H. Pylori*. When reacting urea with urease solution, alkaline ammonia is produced. Therefore, the presence of urease can be detected by determining the pH change during the urea-urease reaction (see col.1, lines 37-67). The bromophenol blue dye on the reaction pad of Jackson '011 is used to detect the change of pH, because it changes color when pH changes. The bromophenol blue dye of Jackson '011 serves only to detect a pH change (pH indicator) rather than a dye for staining a bacteria as disclosed by the present invention. Neither the bromophenol blue dye itself nor its combination with any other substance of Jackson '011 is a staining solution as recited in claim 20

of the present application. Therefore, this difference constitutes another independent basis that none of claim 20, 21 and 25 is anticipated by Jackson '011.

Obviousness Rejection under 35 U.S.C. 103

Based on the anticipation rejection, the Examiner further rejected claims 20, 21, 24, 25, 27 and 28 under 35 U.S.C. 103(a) as being unpatentable over Jackson '011. Specifically, the Examiner stated that the surfactant, the pH buffer and the dye specifically recited in these claims of the present application would have been known by a person of ordinary skill in the art by routine experimentation or optimization based on the teaching of Jackson '011.

We respectfully traverse. As mentioned above, Jackson '011 does not disclose a staining solution nor the buffer for maintaining acidity of the present invention. Jackson '011 and the present invention are respectively directed to different applications and uses different mechanisms. Jackson '011 reacts urea with urease solution to produce ammonia and then applies a pH dye to detect the presence of urease to thereby indirectly determine the presence of *H. Pylori* in a gastric biopsy specimen. The present invention, however, uses the staining solution to stain the bacteria, and thereby directly detecting the presence or amount of bacteria by observing, e.g. the intensity of fluorescence emitted from the stained bacteria.

Jackson '011 does not teach that its reagent for detecting presence of *H. Pylori* in a gastric biopsy specimen can be modified by changing the alkaline pH buffer to acidic buffer, and replacing the pH dye with a staining dye, to make a reagent for detecting a bacteria in a sample, particularly a urine sample, as claimed in the present invention.

Nor is there any motivation for a person of ordinary skill in the art to modify Jackson '011 to make a reagent as claimed in the present invention that uses a different mechanism from Jackson '011. For example, the bromophenol blue dye of Jackson '011 is used to detect a pH change. A person of ordinary skill in the art

would not be motivated to replace the bromophenol blue dye of Jackson '011 with a dye in a staining solution that can stain bacteria and be used for a different purpose from the bromophenol blue dye (pH indicator).

Moreover, even if a person of ordinary skill in the art would try to modify the reagent of Jackson '011, he or she cannot find any direction in Jackson '011 as to how to proceed with the modification proposed by the Examiner, which option would be successful, which substance is critical, particularly given the fact that the reagent of Jackson '011 uses a different mechanism from the present invention.

As clearly stated by MPEP 2143, to establish a *prima facie* case of obviousness, three basic criteria must be met. First, there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings. Second, there must be a reasonable expectation of success. Finally, the prior art reference (or references when combined) must teach or suggest all the claim limitations. The teaching or suggestion to make the claimed combination and the reasonable expectation of success must both be found in the prior art, not in applicant's disclosure. *In re Vaeck*, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991).

As discussed above, in the present case, none of these three criteria is met by the Examiner's rejection, although each of these three criteria must be met to satisfy a proper *prima facie* case of obviousness rejection. Hence, the Examiner's rejection is based on impermissible hindsight at most. Further, if the Examiner is not convinced by the above remarks and insists that a person of ordinary skill in the art would have known how to modify Jackson '011 to arrive at the present invention through routine experimentation, we request that the Examiner provide us with the evidence supporting such an assertion according to MPEP 2144.03. The Examiner should inform us of the teachings in the prior art of each limitation of the claims of the present application, and the motivation to combine those teachings, and the expectation of success of the proposed combination.

The Examiner also rejected claims 20-28 under 35 U.S.C. 103(a) as being unpatentable over Jackson '011 and further in view of Jackson (U.S. patent 5,349,801 "Jackson '801"). Specifically, the Examiner applied

the same reasoning as discussed above to reject claims 20, 21, 24, 25, 27 and 28 as being obvious over Jackson '011. Jackson '801 is used to reject claims 22, 23 and 26 because Jackson '801 discloses the use of N-octyl glucose surfactant. Hence, we traverse the Examiner's rejection of claims 20, 21, 24, 25, 27 and 28 for the same reason fully discussed above. As to claims 22, 23 and 26, we traverse as follows.

As noted above, Jackson '011 fails to disclose the staining solution, and a buffer for maintaining acidity as recited in the claims of the present application. Neither does Jackson '801 teach any of these two limitations. Hence, even if a person of ordinary skill in art had combined the teachings of Jackson '011 and Jackson '801, he or she would still not have obtained the claimed reagent of the present invention.

Further, as to the surfactant taught in Jackson '801, the Examiner acknowledged that it is different from the cationic surfactant recited in the claims of the present invention, but stated that selection of the cationic surfactant based on Jackson '801 would have been well within the purview of the artisan of ordinary skill in the art. The Examiner failed to inform us what was the motivation to make the proposed modification, and why a person of ordinary skill in art would expect success with such a proposed modification. Hence, the Examiner failed to establish a *prima facie* case of obviousness.

In contrast with the Examiner's assertion, we believe that a person of ordinary skill in the art would not have made the modification as the Examiner proposed. Similar to Jackson '011, Jackson '801 is also directed to the detection of *H pylori* in endoscopically obtained biopsy specimen by utilizing the reaction between urea and urease, and detecting the pH change caused by the reaction. The N-octyl glucose surfactant of Jackson '801 is employed to aid in freeing the urease enzyme from the biopsy specimen (see col. 4, lines 44-46). On the other hand, the cationic surfactant of the present invention is used not only to improve the stability of bacterial but also dissolve/shrink mucous fibers, erythrocytes, cell fractures etc. which are present in a sample and thereby reduce the effect on detection of bacteria, as described at page 7, lines 5-10, of the present invention. Hence, a person of ordinary skill in the art would not have modified the surfactant of Jackson '801 to address a problem or attain an object that is different from that of Jackson '801.

The newly added claim 29 is essentially the same as claim 20, except that claim 29 explicitly requires that the dye be capable of staining bacteria. Hence, the newly added claim 29 is neither anticipated by nor obvious over any prior art reference cited by the Examiner for at least the same reason as discussed in connection with claim 20.

It is believed that no fees or charges are required at this time in connection with the present application; however, if any fees or charges are required at this time, they may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE


By Kent H. Cheng
Kent H. Cheng
Reg. No. 33,849
551 Fifth Avenue, Suite 1210
New York, New York 10176
(212) 687-2770

Dated: March 11, 2004

Encl. (Exhibit 1)

PRICED IN ¥

1987



SIGMA

NEW
PRODUCTS

ALPHABETICAL
LIST

BIOACTIVE
PEPTIDES

IMMUNO-
CHEMICALS

MOLECULAR
BIOLOGY

TISSUE
CULTURE

OTHER
PRODUCT
GROUPS

EQUIPMENT
BOOKS AND
SUPPLIES

DIAGNOSTIC
KITS AND
REAGENTS

PRODUCT
INFO

BIOCHEMICALS AND REAGENTS FOR LIFE SCIENCE RESEARCH

カスタマーサービス

フリーダイアル

フリーファックス

: 0120-07-0406

: 0120-67-6788

テクニカルサービス

フリーダイアル

フリーファックス

: 0120-07-0406

: 0120-67-6788

ALPHABETICAL LIST OF COMPOUNDS

ALPHABETICAL LIST OF COMPOUNDS

TRIZMA®

[Tris(hydroxymethyl)aminomethyl]-1,3-propanediol; Tris(hydroxymethyl)aminomethane

- Thoroughly established as an excellent biochemical buffer and basimetric standard.
- Does not precipitate calcium salts. Also of value in maintaining stability of manganese salts.
- Sigma is the pioneer in Tris for laboratory use. The world's most complete stock of Tris compounds.
- McFarland & Norris report on the use of "Sigma 7-9" for greatly reducing mortality of fish in transport.
- See Biological Buffers Section (Page 1783) for other buffers of interest.

PRODUCT NUMBER	SIGMA 7-9*	TRIZMA BASE (Tris(hydroxymethyl)aminomethane)	TRIZMA ACETATE (Tris(hydroxymethyl)aminomethane acetate)	TRIZMA BENZOATE (Tris(hydroxymethyl)aminomethane benzoate)	TRIZMA CARBONATE (Tris(hydroxymethyl)aminomethane carbonate)	TRIZMA CITRATE (Tris(hydroxymethyl)aminomethane citrate)	
T 1378	(Tris(hydroxymethyl)aminomethane) White crystalline powder with slight yellow cast Purity: Minimum 95% (titration) Absorbance 260 [1 cm path vs. H ₂ O]: 0.8 (max.) Water (Karl Fischer): 0.5%	100 g 250 g 500 g 1 kg 5 kg 10 kg 25 kg	3000 4200 5000 8500 49100 87000 194100	3000 4200 5000 8400 15400 60000 109000	3000 4200 5000 8400 15400 60000 109000	3000 4200 5000 8400 15400 60000 109000	3000 4200 5000 8400 15400 60000 109000
T 1391	Heavy metal (as Pb): 5 ppm (max.) A 40% (w/w) solution is clear, pale yellow. [77-36-1] C ₆ H ₁₁ NO ₃ FW 121.1	100 g 250 g 500 g 1 kg 5 kg 10 kg 25 kg	3000 4200 5000 8400 15400 60000 109000	3000 4200 5000 8400 15400 60000 109000	3000 4200 5000 8400 15400 60000 109000	3000 4200 5000 8400 15400 60000 109000	3000 4200 5000 8400 15400 60000 109000
T 1403	White crystalline powder Primary Standard and Buffer Purity: Minimum 95.9% (titration) Absorbance 260 [1 cm path vs. H ₂ O]: 0.05 (max.) Water (Karl Fischer): 0.2% (max.)	25 g 100 g 250 g 500 g 1 kg 5 kg 10 kg	3000 3400 5800 8400 15400 60000 109000	3000 3400 5800 8400 15400 60000 109000	3000 3400 5800 8400 15400 60000 109000	3000 3400 5800 8400 15400 60000 109000	3000 3400 5800 8400 15400 60000 109000

INDICATOR for titrating Trizma
See: 3,4-Dimethylaminino-1-naphthalene-4-methoxybenzenesulfonic acid Page 323

ELECTRODES
For use with Trizma® Buffers
See: Techware Section Page 2275

INDICATOR for titrating Trizma
See: 3,4-Dimethylaminino-1-naphthalene-4-methoxybenzenesulfonic acid Page 323

ELECTRODES
For use with Trizma® Buffers
See: Techware Section Page 2275

T

TRIZMA®

[Tris(hydroxymethyl)aminomethane]

(Continuation of)

TRIZMA BASE

White crystalline powder
Primary Standard and Buffer
Purity: Minimum 95.9% (titration)
Absorbance 260 [1 cm path vs. H₂O]: 0.05
(max.)
Water (Karl Fischer):
0.2% (max.)

The heavy metals (as Pb):

2 ppm (max.)

A 40% (w/w) solution is clear and colorless.
See also: Electrophoresis Reagents Page 1844

Molecular Biology Products Page 1551

Tissue Culture Media and Reagents Page 1633

3. Tissue Culture Media and Reagents Page 1633

4. Tissue Culture Media and Reagents Page 1633

5. Tissue Culture Media and Reagents Page 1633

6. Tissue Culture Media and Reagents Page 1633

7. Tissue Culture Media and Reagents Page 1633

8. Tissue Culture Media and Reagents Page 1633

9. Tissue Culture Media and Reagents Page 1633

10. Tissue Culture Media and Reagents Page 1633

11. Tissue Culture Media and Reagents Page 1633

12. Tissue Culture Media and Reagents Page 1633

13. Tissue Culture Media and Reagents Page 1633

14. Tissue Culture Media and Reagents Page 1633

15. Tissue Culture Media and Reagents Page 1633

16. Tissue Culture Media and Reagents Page 1633

17. Tissue Culture Media and Reagents Page 1633

18. Tissue Culture Media and Reagents Page 1633

19. Tissue Culture Media and Reagents Page 1633

20. Tissue Culture Media and Reagents Page 1633

21. Tissue Culture Media and Reagents Page 1633

22. Tissue Culture Media and Reagents Page 1633

23. Tissue Culture Media and Reagents Page 1633

24. Tissue Culture Media and Reagents Page 1633

25. Tissue Culture Media and Reagents Page 1633

26. Tissue Culture Media and Reagents Page 1633

27. Tissue Culture Media and Reagents Page 1633

28. Tissue Culture Media and Reagents Page 1633

29. Tissue Culture Media and Reagents Page 1633

30. Tissue Culture Media and Reagents Page 1633

31. Tissue Culture Media and Reagents Page 1633

32. Tissue Culture Media and Reagents Page 1633

33. Tissue Culture Media and Reagents Page 1633

34. Tissue Culture Media and Reagents Page 1633

35. Tissue Culture Media and Reagents Page 1633

36. Tissue Culture Media and Reagents Page 1633

37. Tissue Culture Media and Reagents Page 1633

38. Tissue Culture Media and Reagents Page 1633

39. Tissue Culture Media and Reagents Page 1633

40. Tissue Culture Media and Reagents Page 1633

41. Tissue Culture Media and Reagents Page 1633

42. Tissue Culture Media and Reagents Page 1633

43. Tissue Culture Media and Reagents Page 1633

44. Tissue Culture Media and Reagents Page 1633

45. Tissue Culture Media and Reagents Page 1633

46. Tissue Culture Media and Reagents Page 1633

47. Tissue Culture Media and Reagents Page 1633

48. Tissue Culture Media and Reagents Page 1633

49. Tissue Culture Media and Reagents Page 1633

50. Tissue Culture Media and Reagents Page 1633

51. Tissue Culture Media and Reagents Page 1633

52. Tissue Culture Media and Reagents Page 1633

53. Tissue Culture Media and Reagents Page 1633

54. Tissue Culture Media and Reagents Page 1633

55. Tissue Culture Media and Reagents Page 1633

56. Tissue Culture Media and Reagents Page 1633

57. Tissue Culture Media and Reagents Page 1633

58. Tissue Culture Media and Reagents Page 1633

59. Tissue Culture Media and Reagents Page 1633

60. Tissue Culture Media and Reagents Page 1633

61. Tissue Culture Media and Reagents Page 1633

62. Tissue Culture Media and Reagents Page 1633

63. Tissue Culture Media and Reagents Page 1633

64. Tissue Culture Media and Reagents Page 1633

65. Tissue Culture Media and Reagents Page 1633

66. Tissue Culture Media and Reagents Page 1633

67. Tissue Culture Media and Reagents Page 1633

68. Tissue Culture Media and Reagents Page 1633

69. Tissue Culture Media and Reagents Page 1633

70. Tissue Culture Media and Reagents Page 1633

71. Tissue Culture Media and Reagents Page 1633

72. Tissue Culture Media and Reagents Page 1633

73. Tissue Culture Media and Reagents Page 1633

74. Tissue Culture Media and Reagents Page 1633

75. Tissue Culture Media and Reagents Page 1633

76. Tissue Culture Media and Reagents Page 1633

77. Tissue Culture Media and Reagents Page 1633

78. Tissue Culture Media and Reagents Page 1633

79. Tissue Culture Media and Reagents Page 1633

80. Tissue Culture Media and Reagents Page 1633

81. Tissue Culture Media and Reagents Page 1633

82. Tissue Culture Media and Reagents Page 1633

83. Tissue Culture Media and Reagents Page 1633

84. Tissue Culture Media and Reagents Page 1633

85. Tissue Culture Media and Reagents Page 1633

86. Tissue Culture Media and Reagents Page 1633

87. Tissue Culture Media and Reagents Page 1633

88. Tissue Culture Media and Reagents Page 1633

89. Tissue Culture Media and Reagents Page 1633

90. Tissue Culture Media and Reagents Page 1633

91. Tissue Culture Media and Reagents Page 1633

92. Tissue Culture Media and Reagents Page 1633

93. Tissue Culture Media and Reagents Page 1633

94. Tissue Culture Media and Reagents Page 1633

95. Tissue Culture Media and Reagents Page 1633

96. Tissue Culture Media and Reagents Page 1633

97. Tissue Culture Media and Reagents Page 1633

98. Tissue Culture Media and Reagents Page 1633

99. Tissue Culture Media and Reagents Page 1633

100. Tissue Culture Media and Reagents Page 1633

101. Tissue Culture Media and Reagents Page 1633

102. Tissue Culture Media and Reagents Page 1633

103. Tissue Culture Media and Reagents Page 1633

104. Tissue Culture Media and Reagents Page 1633

105. Tissue Culture Media and Reagents Page 1633

106. Tissue Culture Media and Reagents Page 1633

107. Tissue Culture Media and Reagents Page 1633

108. Tissue Culture Media and Reagents Page 1633

109. Tissue Culture Media and Reagents Page 1633

110. Tissue Culture Media and Reagents Page 1633

111. Tissue Culture Media and Reagents Page 1633

112. Tissue Culture Media and Reagents Page 1633

113. Tissue Culture Media and Reagents Page 1633

114. Tissue Culture Media and Reagents Page 1633

115. Tissue Culture Media and Reagents Page 1633

116. Tissue Culture Media and Reagents Page 1633

117. Tissue Culture Media and Reagents Page 1633

118. Tissue Culture Media and Reagents Page 1633

119. Tissue Culture Media and Reagents Page 1633

120. Tissue Culture Media and Reagents Page 1633

121. Tissue Culture Media and Reagents Page 1633

122. Tissue Culture Media and Reagents Page 1633

123. Tissue Culture Media and Reagents Page 1633

124. Tissue Culture Media and Reagents Page 1633

125. Tissue Culture Media and Reagents Page 1633

126. Tissue Culture Media and Reagents Page 1633

127. Tissue Culture Media and Reagents Page 1633

128. Tissue Culture Media and Reagents Page 1633

129. Tissue Culture Media and Reagents Page 1633

130. Tissue Culture Media and Reagents Page 1633

131. Tissue Culture Media and Reagents Page 1633

132. Tissue Culture Media and Reagents Page 1633

133. Tissue Culture Media and Reagents Page 1633

134. Tissue Culture Media and Reagents Page 1633

135. Tissue Culture Media and Reagents Page 1633

136. Tissue Culture Media and Reagents Page 1633

137. Tissue Culture Media and Reagents Page 1633

138. Tissue Culture Media and Reagents Page 1633

139. Tissue Culture Media and Reagents Page 1633

140. Tissue Culture Media and Reagents Page 1633

141. Tissue Culture Media and Reagents Page 1633

142. Tissue Culture Media and Reagents Page 1633

143. Tissue Culture Media and Reagents Page 1633

144. Tissue Culture Media and Reagents Page 1633

145. Tissue Culture Media and Reagents Page 1633

146. Tissue Culture Media and Reagents Page 1633

147. Tissue Culture Media and Reagents Page 1633

148. Tissue Culture Media and Reagents Page 1633

149. Tissue Culture Media and Reagents Page 1633

150. Tissue Culture Media and Reagents Page 1633

151. Tissue Culture Media and Reagents Page 1633

152. Tissue Culture Media and Reagents Page 1633

153. Tissue Culture Media and Reagents Page 1633

154. Tissue Culture Media and Reagents Page 1633

155. Tissue Culture Media and Reagents Page 1633

156. Tissue Culture Media and Reagents Page 1633

157. Tissue Culture Media and Reagents Page 1633

158. Tissue Culture Media and Reagents Page 1633

159. Tissue Culture Media and Reagents Page 1633

160. Tissue Culture Media and Reagents Page 1633

161. Tissue Culture Media and Reagents Page 1633

162. Tissue Culture Media and Reagents Page 1633

163. Tissue Culture Media and Reagents Page 1633

164. Tissue Culture Media and Reagents Page 1633

165. Tissue Culture Media and Reagents Page 1633

166. Tissue Culture Media and Reagents Page 1633